SCHEMBL24328563

SCHEMBL24328563

CC1Cc2c(N3CCC(N(C)C)CC3)ccc(N)c2O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.40
TIPARP Q7Z3E1 1/20 0.36
GAA P10253 5/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 4/20 0.34
HTT P42858 2/20 0.34
KDM4E B2RXH2 3/20 0.33
POLB P06746 2/20 0.33
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
NR4A1 P22736 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL3 Q96JM7 1/20 0.33
PTPN11 Q06124 1/20 0.32
MAP4K4 O95819 1/20 0.32
MAPT P10636 4/20 0.32
NPC1 O15118 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29661326 1.00 PARP1 (0.40) PARP1TIPARPGAAMEN1KMT2A
SCHEMBL26655456 0.79 CTSB (0.40) GAAMEN1KMT2AUSP2ALDH1A1
SCHEMBL26655419 0.79 GAA (0.39) PARP1GAAMEN1KMT2AUSP2
SCHEMBL29661397 0.78 TIPARP (0.34) TIPARPGAAMEN1KMT2AUSP2
SCHEMBL24327498 0.78 TIPARP (0.34) TIPARPGAAMEN1KMT2AUSP2
SCHEMBL24328564 0.78 GAA (0.43) TIPARPGAAMEN1KMT2AUSP2
SCHEMBL24328516 0.77 PDCD1 (0.42) GAAMEN1KMT2AUSP2ALDH1A1
SCHEMBL29661403 0.77 PDCD1 (0.37) TIPARPGAAMEN1KMT2AUSP2
SCHEMBL29661286 0.77 PDCD1 (0.42) GAAMEN1KMT2AUSP2ALDH1A1
SCHEMBL24327378 0.77 PDCD1 (0.37) TIPARPGAAMEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 PARP1 1826/4885TIPARP 888/4885GAA 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.